The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors
Identifieur interne : 000999 ( Istex/Curation ); précédent : 000998; suivant : 000A00The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors
Auteurs : Rachael S. Felberbaum [États-Unis]Source :
- Biotechnology Journal [ 1860-6768 ] ; 2015-05.
Abstract
The baculovirus expression vector system (BEVS) platform has become an established manufacturing platform for the production of viral vaccines and gene therapy vectors. Nine BEVS‐derived products have been approved – four for human use (Cervarix®, Provenge®, Glybera® and Flublok®) and five for veterinary use (Porcilis® Pesti, BAYOVAC CSF E2®, Circumvent® PCV, Ingelvac CircoFLEX® and Porcilis® PCV). The BEVS platform offers many advantages, including manufacturing speed, flexible product design, inherent safety and scalability. This combination of features and product approvals has previously attracted interest from academic researchers, and more recently from industry leaders, to utilize BEVS to develop next generation vaccines, vectors for gene therapy, and other biopharmaceutical complex proteins. In this review, we explore the BEVS platform, detailing how it works, platform features and limitations and important considerations for manufacturing and regulatory approval. To underscore the growth in opportunities for BEVS‐derived products, we discuss the latest product developments in the gene therapy and influenza vaccine fields that follow in the wake of the recent product approvals of Glybera® and Flublok®, respectively. We anticipate that the utility of the platform will expand even further as new BEVS‐derived products attain licensure. Finally, we touch on some of the areas where new BEVS‐derived products are likely to emerge.
The baculovirus expression vector system (BEVS) has become an established commercial manufacturing platform. The authors review this technology, which enables fast, flexible and scalable protein production and is increasingly being used for the production of viral vaccines and gene therapy vectors. Nine BEVS‐derived products have been licensed by global regulatory authorities, paving the way for new products that are in development.
Url:
DOI: 10.1002/biot.201400438
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000999
Links to Exploration step
ISTEX:B294EB921F41F8D7654A04E9AC4BE437F004790DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors</title><author><name sortKey="Felberbaum, Rachael S" sort="Felberbaum, Rachael S" uniqKey="Felberbaum R" first="Rachael S." last="Felberbaum">Rachael S. Felberbaum</name><affiliation wicri:level="1"><mods:affiliation>Protein Sciences Corporation, Meriden, CT, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Protein Sciences Corporation, Meriden, CT</wicri:regionArea></affiliation><affiliation><mods:affiliation>E-mail: rfelberbaum@proteinsciences.com</mods:affiliation><wicri:noCountry code="no comma">E-mail: rfelberbaum@proteinsciences.com</wicri:noCountry></affiliation><affiliation wicri:level="2"><mods:affiliation>Correspondence address: Correspondence: Dr. Rachael Felberbaum, Senior Director, Business Development, Protein Sciences Corporation, 1000 Research Parkway, Meriden, CT 06450 USA</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Correspondence address: Correspondence: Dr. Rachael Felberbaum, Senior Director, Business Development, Protein Sciences Corporation, 1000 Research Parkway, Meriden</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B294EB921F41F8D7654A04E9AC4BE437F004790D</idno><date when="2015" year="2015">2015</date><idno type="doi">10.1002/biot.201400438</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-C4V1L7GV-1/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000999</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000999</idno><idno type="wicri:Area/Istex/Curation">000999</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors</title><author><name sortKey="Felberbaum, Rachael S" sort="Felberbaum, Rachael S" uniqKey="Felberbaum R" first="Rachael S." last="Felberbaum">Rachael S. Felberbaum</name><affiliation wicri:level="1"><mods:affiliation>Protein Sciences Corporation, Meriden, CT, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Protein Sciences Corporation, Meriden, CT</wicri:regionArea></affiliation><affiliation><mods:affiliation>E-mail: rfelberbaum@proteinsciences.com</mods:affiliation></affiliation><affiliation wicri:level="2"><mods:affiliation>Correspondence address: Correspondence: Dr. Rachael Felberbaum, Senior Director, Business Development, Protein Sciences Corporation, 1000 Research Parkway, Meriden, CT 06450 USA</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Correspondence address: Correspondence: Dr. Rachael Felberbaum, Senior Director, Business Development, Protein Sciences Corporation, 1000 Research Parkway, Meriden</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Biotechnology Journal</title><title level="j" type="sub">Vaccine Biotechnology</title><title level="j" type="alt">BIOTECHNOLOGY JOURNAL</title><idno type="ISSN">1860-6768</idno><idno type="eISSN">1860-7314</idno><imprint><biblScope unit="vol">10</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="702">702</biblScope><biblScope unit="page" to="714">714</biblScope><biblScope unit="page-count">13</biblScope><publisher>WILEY‐VCH Verlag</publisher><pubPlace>Weinheim</pubPlace><date type="published" when="2015-05">2015-05</date></imprint><idno type="ISSN">1860-6768</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1860-6768</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The baculovirus expression vector system (BEVS) platform has become an established manufacturing platform for the production of viral vaccines and gene therapy vectors. Nine BEVS‐derived products have been approved – four for human use (Cervarix®, Provenge®, Glybera® and Flublok®) and five for veterinary use (Porcilis® Pesti, BAYOVAC CSF E2®, Circumvent® PCV, Ingelvac CircoFLEX® and Porcilis® PCV). The BEVS platform offers many advantages, including manufacturing speed, flexible product design, inherent safety and scalability. This combination of features and product approvals has previously attracted interest from academic researchers, and more recently from industry leaders, to utilize BEVS to develop next generation vaccines, vectors for gene therapy, and other biopharmaceutical complex proteins. In this review, we explore the BEVS platform, detailing how it works, platform features and limitations and important considerations for manufacturing and regulatory approval. To underscore the growth in opportunities for BEVS‐derived products, we discuss the latest product developments in the gene therapy and influenza vaccine fields that follow in the wake of the recent product approvals of Glybera® and Flublok®, respectively. We anticipate that the utility of the platform will expand even further as new BEVS‐derived products attain licensure. Finally, we touch on some of the areas where new BEVS‐derived products are likely to emerge.</div><div type="abstract" xml:lang="en">The baculovirus expression vector system (BEVS) has become an established commercial manufacturing platform. The authors review this technology, which enables fast, flexible and scalable protein production and is increasingly being used for the production of viral vaccines and gene therapy vectors. Nine BEVS‐derived products have been licensed by global regulatory authorities, paving the way for new products that are in development.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000999 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000999 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:B294EB921F41F8D7654A04E9AC4BE437F004790D
|texte= The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors
}}
| This area was generated with Dilib version V0.6.33. |  |